Innate Pharma S.A.
Innate Pharma S.A. (IPHA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ipha · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$5.00
Consensus
$3.50
+98.9% upside
Low
$2.00
Median: $3.5 · Last Close: $1.76
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$3.50
98.9% upside
High Target
$5
184.1%
Low Target
$2
13.6%
Current Price
$1.76
as of today
Based on analyst price targets, the IPHA stock price prediction for the next 12 months ranges from $2 to $5. The consensus IPHA price forecast of $3.50 implies 98.9% upside from the current price of $1.76.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.73 | ↓ 1.46% |
1-day model range: $1.69–$1.78. Peak: $1.78 (-1.46%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IPHA · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-29 | BTIG | Maintains | Buy→Buy |
| 2025-10-29 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2025-09-18 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-04-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Innate Pharma S.A. (IPHA) stock. Of the recent 34 rating actions, 3 were upgrades and 3 were downgrades. 6 analysts currently cover IPHA.
Analyst Recommendation Trends
IPHA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$31M
↓ 24.1% YoY
Revenue Next Year
$64M
↑ 106.8% YoY
EPS This Year
$-0.25
EPS Next Year
$0.04
↓ 117.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast IPHA EPS of $-0.25 for the current fiscal year, based on estimates from 2 analysts. The IPHA revenue forecast is $31M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IPHA stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IPHA price target is $3.50 (+98.9% upside), with an analyst consensus of Buy.
The IPHA short-term stock prediction for tomorrow is $1.73 (-1.46%). The IPHA stock price prediction for 2027 estimates an average of $1. The IPHA stock prediction for 2030 projects a range of $0–$1.
Innate Pharma S.A. trades on NASDAQ under the ticker IPHA. The IPHA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
IPHA forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month IPHA price target is $3.50, with a high forecast of $5.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +98.9% potential upside from the current price of $1.76.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.